A Phase 4 interventional study of Azithropycin according to symptoms and Azithromycin according to rheology or symptoms in Chronic Obstructive Pulmonary Disease, sponsored by University Hospital, Montpellier. Recruiting at 3 sites in France. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-24.
Sponsored by University Hospital, Montpellier · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier — 2 open to participants now, 2 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · University Hospital, Montpellier.
Among the 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is the only one in phase 4, and was the 14th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier are open now, in 1 country. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is above the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 50 across the 11 interventional studies, 30 across the 7 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.
1 of the studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04339270University Hospital, MontpellierChronic Airway Disease, Mucus Rheology and Exacerbations | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Pulmonary Disease, Chronic Obstructive by University Hospital, Montpellier, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main objective of this trial is to compare the exacerbation number over 12 months of follow-up between a group of patients with COPD treated according to standardized management (azithromycin prescribed in the event of severe sputum according to the CASA-Q score , standardized comparator arm) and a similar group in which azithromycin is prescribed based on mucus rheology (experimental arm) or CASA-Q.
The secondary objectives are to compare between the 2 arms:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to this arm will be prescribed azithromycin in function of their symptoms.
Drug: Azithropycin according to symptoms
Patients randomized to this arm will be prescribed azithromycin in function of their sputum rheology.
Drug: Azithromycin according to rheology or symptoms
Patients randomized to the "standardized comparator arm" will benefit from the standard treatment for COPD, including with regard to the prescription of azithromycin in case of severe sputum complaints (here defined by a CASA-Q sputum symptoms score \<70 to homogenize practices between centers). CASA-Q will be evaluated every 3 months. * If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70. * If the patient has a sputum symptoms score\> 70, management is not changed.
Treatment according to standard COPD management, except for the prescription of azithromycin, which will be prescribed in function of mucus rheology or as a function of sputum complaints (here defined by a CASA-Q sputum symptoms score \<70). The rheology of mucus will be quantified every 3 months. * If the patient has spontaneous or induced sputum, and this sputum has a critical constraint (tau-C) \> 39, a prescription for 3 months of azithromycin treatment will be initiated. This prescription may be renewed every 3 months during the 12 months of follow-up planned in this study. * If the patient has a sputum symptoms score \<70, a prescription for 3 months of azithromycin treatment will be initiated. This prescription can be renewed every 3 months during the 12 months of follow-up planned in this study, if the patient continues to obtain a sputum symptoms score \<70. * If the patient has a sputum symptoms score\> 70, management is not changed.
The main outcome measure is the number of exacerbations over the 12 months of follow-up.
An exacerbation is defined according to French recommendations as an "acute event characterized by worsening of respiratory symptoms (notably cough, sputum and dyspnea) beyond \[normal\] daily variation and leading to a modification of treatment: either a simple increase in bronchodilators (in this case, a duration greater than 24 hours is required to define an exacerbation) or the addition of another treatment (antibiotic therapy and / or oral corticosteroid therapy)."
Time frame: 12 months
The number of mild exacerbations throughout follow-up
A mild exacerbation does not require new additional medicine.
Time frame: 12 months
The number of moderate exacerbations throughout follow-up
Moderate exacerbations require antibiotics or oral corticosteroids (but not hospitalization).
Time frame: 12 months
The number of severe exacerbations throughout follow-up
Severe exacerbations require hospitalization.
Time frame: 12 months
COPD Assessment Test (CAT)
Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.
Time frame: Baseline (Day 0)
COPD Assessment Test (CAT)
Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.
Time frame: 3 months
COPD Assessment Test (CAT)
Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.
Time frame: 6 months
COPD Assessment Test (CAT)
Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.
Time frame: 9 months
COPD Assessment Test (CAT)
Scores range from 0-40 with higher scores indicative of greater COPD impact on health status.
Time frame: 12 months
Sino Nasal Outcome Test 22
The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).
Time frame: Baseline (Day 0)
Sino Nasal Outcome Test 22
The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).
Time frame: 3 months
Sino Nasal Outcome Test 22
The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).
Time frame: 6 months
Sino Nasal Outcome Test 22
The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).
Time frame: 9 months
Sino Nasal Outcome Test 22
The 22-question SNOT-22 is scored as 0 (no problem) to 5 (problem as bad as it can be) with a total range from 0 to 110 (higher scores indicate poorer outcomes).
Time frame: 12 months
Cough and sputum assessment questionnaire (CASA-Q)
The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.
Time frame: Baseline (Day 0)
Cough and sputum assessment questionnaire (CASA-Q)
The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.
Time frame: 3 months
Cough and sputum assessment questionnaire (CASA-Q)
The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.
Time frame: 6 months
Cough and sputum assessment questionnaire (CASA-Q)
The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.
Time frame: 9 months
Cough and sputum assessment questionnaire (CASA-Q)
The four domains of the CASA-Q (cough/sputum symptom and impact) use scales from 0 to 100, with lower scores indicating higher symptom/impact levels. The 20-item questionnaire with a 7-day recall assesses the frequency and severity of cough and sputum and their impact on everyday life in clinical (trial) settings.
Time frame: 12 months
Visual analogue scale for dyspnea
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).
Time frame: Baseline (Day 0)
Visual analogue scale for dyspnea
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).
Time frame: 3 months
Visual analogue scale for dyspnea
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).
Time frame: 6 months
Visual analogue scale for dyspnea
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).
Time frame: 9 months
Visual analogue scale for dyspnea
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of dyspnea possible).
Time frame: 12 months
Visual analogue scale for coughing
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).
Time frame: Baseline (Day 0)
Visual analogue scale for coughing
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).
Time frame: 3 months
Visual analogue scale for coughing
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).
Time frame: 6 months
Visual analogue scale for coughing
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).
Time frame: 9 months
Visual analogue scale for coughing
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of coughing possible).
Time frame: 12 months
Visual analogue scale for sputum production
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).
Time frame: Baseline (Day 0)
Visual analogue scale for sputum production
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).
Time frame: 3 months
Visual analogue scale for sputum production
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).
Time frame: 6 months
Visual analogue scale for sputum production
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).
Time frame: 9 months
Visual analogue scale for sputum production
A patient-reported visual analogue scale (VAS) starting at 0 (no symptoms) and ending at 100 (the worst possible level of sputum production possible).
Time frame: 12 months
Rheology: modulus of elasticity of mucus (G ')
Time frame: Baseline (Day 0)
Rheology: modulus of elasticity of mucus (G ')
Time frame: 3 months
Rheology: modulus of elasticity of mucus (G ')
Time frame: 6 months
Rheology: modulus of elasticity of mucus (G ')
Time frame: 9 months
Rheology: modulus of elasticity of mucus (G ')
Time frame: 12 months
Rheology: the viscous module (G '')
Time frame: Baseline (Day 0)
Rheology: the viscous module (G '')
Time frame: 3 months
Rheology: the viscous module (G '')
Time frame: 6 months
Rheology: the viscous module (G '')
Time frame: 9 months
Rheology: the viscous module (G '')
Time frame: 12 months
Rheology: The ratio G '' / G '
Time frame: Baseline (Day 0)
Rheology: The ratio G '' / G '
Time frame: 3 months
Rheology: The ratio G '' / G '
Time frame: 6 months
Rheology: The ratio G '' / G '
Time frame: 9 months
Rheology: The ratio G '' / G '
Time frame: 12 months
Rheology: the critical constraint (tau-C).
Time frame: Baseline (Day 0)
Rheology: the critical constraint (tau-C).
Time frame: 3 months
Rheology: the critical constraint (tau-C).
Time frame: 6 months
Rheology: the critical constraint (tau-C).
Time frame: 9 months
Rheology: the critical constraint (tau-C).
Time frame: 12 months
Spirometry: forced expiratory volume in 1 minute (FEV1)
Time frame: Baseline (day 0)
Spirometry: forced expiratory volume in 1 minute (FEV1)
Time frame: 3 months
Spirometry: forced expiratory volume in 1 minute (FEV1)
Time frame: 6 months
Spirometry: forced expiratory volume in 1 minute (FEV1)
Time frame: 9 months
Spirometry: forced expiratory volume in 1 minute (FEV1)
Time frame: 12 months
Spirometry: forced vital capacity (FVC)
Time frame: Baseline (day 0)
Spirometry: forced vital capacity (FVC)
Time frame: 3 months
Spirometry: forced vital capacity (FVC)
Time frame: 6 months
Spirometry: forced vital capacity (FVC)
Time frame: 9 months
Spirometry: forced vital capacity (FVC)
Time frame: 12 months
Spirometry: FEV1/FVC
Time frame: Baseline (day 0)
Spirometry: FEV1/FVC
Time frame: 3 months
Spirometry: FEV1/FVC
Time frame: 6 months
Spirometry: FEV1/FVC
Time frame: 9 months
Spirometry: FEV1/FVC
Time frame: 12 months
Plethysmography for lung volumes: residual volume (RV)
Time frame: Baseline (day 0)
Plethysmography for lung volumes: residual volume (RV)
Time frame: 3 months
Plethysmography for lung volumes: residual volume (RV)
Time frame: 6 months
Plethysmography for lung volumes: residual volume (RV)
Time frame: 9 months
Plethysmography for lung volumes: residual volume (RV)
Time frame: 12 months
Plethysmography for lung volumes: functional residual capacity (FRC)
Time frame: Baseline (day 0)
Plethysmography for lung volumes: functional residual capacity (FRC)
Time frame: 3 months
Plethysmography for lung volumes: functional residual capacity (FRC)
Time frame: 6 months
Plethysmography for lung volumes: functional residual capacity (FRC)
Time frame: 9 months
Plethysmography for lung volumes: functional residual capacity (FRC)
Time frame: 12 months
Plethysmography for lung volumes: total lung capacity (TLC)
Time frame: Baseline (day 0)
Plethysmography for lung volumes: total lung capacity (TLC)
Time frame: 3 months
Plethysmography for lung volumes: total lung capacity (TLC)
Time frame: 6 months
Plethysmography for lung volumes: total lung capacity (TLC)
Time frame: 9 months
Plethysmography for lung volumes: total lung capacity (TLC)
Time frame: 12 months
Plethysmography for lung volumes: RV/TLC
Time frame: Baseline (day 0)
Plethysmography for lung volumes: RV/TLC
Time frame: 3 months
Plethysmography for lung volumes: RV/TLC
Time frame: 6 months
Plethysmography for lung volumes: RV/TLC
Time frame: 9 months
Plethysmography for lung volumes: RV/TLC
Time frame: 12 months
Drug consumption throughout the study.
Time frame: 12 months
The number of adverse events will be recorded throughout the study.
Time frame: 12 months
Episodes of exacerbation throughout the study
For each exacerbation, the beginning and end dates will be recorded.
Time frame: 12 months
Episodes of hospitalization throughout the study
For each hospitalization, the beginning and end dates will be recorded.
Time frame: 12 months
Clinical improvement
Clinical improvement is scored via a point system from 0 to 3 at the end of the study. The points are added-up as follows: * 1 point: no more than one exacerbation without hospitalization during the 52 weeks of follow-up; * 1 point: gain \> 100mL in pre-bronchodilator FEV1 at the 52nd week compared to the baseline state; * 1 point: variation of the CAT score during the 52 weeks of observation \> 2.
Time frame: 12 months
Medical outcomes study 36-Item Short Form Survey (SF-36)
The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time frame: Baseline (day 0)
Medical outcomes study 36-Item Short Form Survey (SF-36)
The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time frame: 3 months
Medical outcomes study 36-Item Short Form Survey (SF-36)
The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time frame: 6 months
Medical outcomes study 36-Item Short Form Survey (SF-36)
The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time frame: 9 months
Medical outcomes study 36-Item Short Form Survey (SF-36)
The SF-36 taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. A score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time frame: 12 months
EQ-5D-5L
In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.
Time frame: Baseline (day 0)
EQ-5D-5L
In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.
Time frame: 3 months
EQ-5D-5L
In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.
Time frame: 6 months
EQ-5D-5L
In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.
Time frame: 9 months
EQ-5D-5L
In its original version, this self-administered questionnaire consists of two pages: the first contains the EQ-5D descriptive system and the second a visual analogue scale. The descriptive system has five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each described by five levels of intensity ("no problems", "slight problems", "moderate problems", "severe problems" and "extreme problems or complete inability"). The respondent must indicate one intensity level for each dimension.
Time frame: 12 months
St-George's Respiratory Questionnaire
Scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: Baseline (day 0)
St-George's Respiratory Questionnaire
Scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: 3 months
St-George's Respiratory Questionnaire
Scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: 6 months
St-George's Respiratory Questionnaire
Scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: 9 months
St-George's Respiratory Questionnaire
Scores range from 0 to 100, with higher scores indicating more limitations.
Time frame: 12 months
Blood cell differential: neutrophil levels
A complete blood cell differential will be taken, including neutrophilia and eosinophilia.
Time frame: Baseline (day 0)
Blood cell differential: eosinophil levels
A complete blood cell differential will be taken, including neutrophilia and eosinophilia.
Time frame: Baseline (day 0)
Blood cell differential: neutrophil levels
A complete blood cell differential will be taken, including neutrophilia and eosinophilia.
Time frame: 12 months
Blood cell differential: eosinophil levels
A complete blood cell differential will be taken, including neutrophilia and eosinophilia.
Time frame: 12 months
Serum Club cell secretory protein
Time frame: Baseline (day 0)
Serum Club cell secretory protein
Time frame: 12 months
Sputum bacteriology
Time frame: Baseline (day 0)
Sputum bacteriology
Time frame: 12 months
Plan to share: Yes — The general goal is to make the study data available to interested researchers as well as to provide proof of transparency for the study. Data (and an accompanying data dictionary) will be de-identified and potentially further cleaned or aggregated as the investigators deem necessary to protect participant anonymity. Data will be made available to persons who address a reasonable request to the study director and fulfil the requirements stipulated by the French CNIL (Commission Nationale de l'Informatique et des Libertés : https://www.cnil.fr/professionnel).
Time frame: As close to "real time" as possible, the following supporting information will be made public: Study Protocol (to be published in an appropriate journal). Statistical Analysis Plan Participant Information materials Analytic code These will be posted and registered on osf.io and/or clinicaltrials.gov (if not published). Datasets can be requested after the publication process has been completed.
Access criteria: The conditions under which members of the public will be granted access to datasets are: The data will be used/examined in a not-for-profit manner; The data will not be used in an attempt to identify a participant or group of participants; The user does not work for a private insurance company; The data will not be used in support of any kind of private insurance policy or health penalties; The data will be used/examined for the advancement of science/teaching while respecting participant/patient privacy and rights; The user will state why they wish to access the data. The appropriate CNIL approval has been obtained by the user.
Data sharing details ↗ · osf.io
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Feb 2027, 48 months after the start.
Of 86 non-industry phase 4 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 48 months is above that.
Counting every sponsor, half of 157 studies reached it within 19 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
University Hospital, Montpellier →